Article Text

Download PDFPDF

Extended report
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
  1. A Strangfeld1,
  2. A Richter1,
  3. B Siegmund2,
  4. P Herzer3,
  5. K Rockwitz4,
  6. W Demary5,
  7. M Aringer6,
  8. Y Meißner1,
  9. A Zink1,2,
  10. J Listing1
  1. 1Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
  2. 2Centrum Innere Medizin mit Gastroenterologie und Nephrologie CC 13, Charité University Medicine Berlin, Berlin, Germany
  3. 3Scientific Advisory Board, Munich, Germany
  4. 4Goslar, Germany
  5. 5Hildesheim, Germany
  6. 6Department of Internal Medicine III, Division of Rheumatology, University Medicine Dresden, Dresden, Germany
  1. Correspondence to Dr Anja Strangfeld, Deutsches Rheuma-Forschungszentrum Berlin, Ein Leibniz Institut, Programmbereich Epidemiologie, Charitéplatz 1, Berlin 10117, Germany; strangfeld{at}drfz.de

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.